Previous 10 | Next 10 |
Live moderated webcast fireside chat on August 3 rd at 11:35 AM ET HOUSTON, TX / ACCESSWIRE / August 3, 2023 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic can...
Company continued to see rapid progression and acceleration of enrollment with 180 patients enrolled to date across 46 clinical trial sites, globally Completion of enrollment of study expected by end of 2023 Company has documented the necessary number of patients reaching the primary ef...
Estimates from the American Cancer Society show that doctors will diagnose around 24,000 malignant spinal cord or brain tumors this year, with an estimated 18,990 people losing their lives to the condition. Gliomas are a class of tumors that grow on the brain or spinal cord, applying pressure...
CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today announced that its abstract was selected for in-person poster presentation at the 2...
HOUSTON, TX / ACCESSWIRE / July 27, 2023 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its ab...
Researchers from Henry Ford Health’s Hermelin Brain Tumor Center have begun working on a brain cancer treatment that would use modified viruses to fight cancer cells. Hermelin Brain Tumor Center scientists are currently in the midst of a phase 1 clinical trial for a cutting-edge brain ca...
National awareness of glioblastoma tumors (“GBM”) sustained by Congressional leaders aim to improve efforts to treat brain cancers and ultimately improve patient survival GBM is a widely occurring, aggressive and effectively incurable brain cancer that few patients survive beyond ...
Researchers from Mass General Cancer Center’s Central Nervous System Metastasis Center have devised a way to shrink brain tumors by up to 90% using already existing drugs . The researchers used two cancer drugs approved to treat melanoma to treat papillary craniopharyngioma (PCP), a rar...
Scientists from Harvard University have created an artificial intelligence (AI) tool that would enable physicians to do real-time genetic analysis of brain tumors during surgery. Brain tumors often have poor treatment outcomes because their proximity to the brain makes treating them effective...
Although cancer treatments have come quite a long way in terms of improving health outcomes and post-diagnosis expectancy rates, treatment is rarely ever pleasant . Most cancer patients who undergo treatments such as chemotherapy will experience side effects including hair loss, anemia, infect...
News, Short Squeeze, Breakout and More Instantly...
CNS Pharmaceuticals Inc. Company Name:
CNSP Stock Symbol:
NYSE Market:
CNS Pharmaceuticals Inc. Website:
New research suggests that cancer may have been plaguing individuals even thousands of years ago. Researchers at the University of Cambridge’s Duckworth Laboratory Collection studied skulls obtained from Ancient Egypt, observing lesions which they believe may have been left by malignant t...
CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be featured in tomorrow’s Virtual Investor Closing Bell Series. According to the announcemen...
Live video webcast with Chief Executive Officer, John Climaco, on Wednesday, June 17 th at 4:00 PM ET HOUSTON, TX / ACCESSWIRE / July 16, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatm...